Long-term clinical and hemodynamic evaluation of the Ionescu-Shiley pericardial xenograft and the Braunwald-Cutter and Björk-Shiley prostheses in the mitral position

Tandon, Anand P.; Sengupta, Somen M.; Lukács, L; Ionescu, Marian I.; Shumaker, Harris B

doi:10.1016/s0022-5223(19)39552-2

Cited by 31 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3-5). In general, our hemodynamic results are in agreement with those previously reported by Tandon et al [6,71. However, our results for chronic intravascular hemolysis are different from those reported by those investigators [7]. They reported that patients with the Ionescu-Shiley valve did not show any evidence of hemolysis.…”

Section: Discussioncontrasting

confidence: 99%

“…Valve thrombosis has not been encountered in his entire series. The structural integrity of the Ionescu-Shiley xenograft has been maintained, as shown by six years of clinical experience and by more than seven years of in vitro testing [6,7]. No tissue valve failure has been found in our series.…”

Section: Brauiiiald-mentioning

confidence: 52%

“…Hetzer et al [19] reported the possible beneficial effects of aspirin in further reducing the risk of thromboembolism. Furthermore, Tandon et al [6,7], have reported that the pericardial xenograft in the mitral position has generated a very small number of transient embolic phenomena, none of which occurred beyond six weeks postoperatively, despite the fact that long-term anticoagulation was not used. Based on these data, we elected to discontinue anticoagulation therapy after the third month postoperation if the patient was in sinus rhythm and had no other risk factors for thromboembolism.…”

Section: Brauiiiald-mentioning

confidence: 99%

“…Based on these data, we elected to discontinue anticoagulation therapy after the third month postoperation if the patient was in sinus rhythm and had no other risk factors for thromboembolism. Ionescu reports an incidence of embolization of 1.5 episodes per 100 patient-years with the PX compared with an incidence of embolization of 4.7 episodes per 100 patient-years with the Bjork-Shiley valve [7]. Thus, the PX is superior to most mechanical prosthetic valves in reducing the incidence of thromboembolism, even without use of long-term anticoagulation.…”

Section: Brauiiiald-mentioning

confidence: 99%

See 3 more Smart Citations

Hemodynamic assessment of the lonescu‐shiley pericardial xenograft in the mitral position

Febres‐Roman

Haas

Cowen

1980

Cathet. Cardiovasc. Diagn.

View full text Add to dashboard Cite

While the very low thrombogenicity without anticoagulant therapy and generally good durability of the lonescu-Shiley bioprosthesis has been demonstrated, further hemodynamic assessment is necessary. The present study assessed cardiac function and heterograft performance during right and left heart catheterization at rest and exercise (three to six months postoperation) of eight patients with severe mitral stenosis and/or regurgitation prior to surgery. We found, comparing pre- and postoperative resting values, that mean pulmonary artery pressure decreased (32 +/- 2.7 to 22 +/- 3.5 mm Hg; P < 0.02), cardiac index increased (2.1 +/- 0.09 to 2.5 +/- 0.13 liters/min/m2; P < 0.01), pulmonary wedge pressure decreased (21 +/- 2.3 to 13 +/- 1.8 mm Hg; P < 0.01), and the clinical status (NYHA) improved markedly. Mean diastolic gradient across the pericardial xenograft was 6.1 +/- 1.1 mm Hg at rest and 14.6 +/- 2.3 mm Hg on exercise. The calculated xenograft surface area was 1.7 cm2 at rest and 2.0 cm2 during exercise. No regurgitation was detected in seven of eight patients. Thus, mitral lonescu-Shiley bioprosthesis provide excellent heterograft function.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Brauiiiald-mentioning

confidence: 52%

Section: Brauiiiald-mentioning

confidence: 99%

Section: Brauiiiald-mentioning

confidence: 99%

See 2 more Smart Citations

Hemodynamic assessment of the lonescu‐shiley pericardial xenograft in the mitral position

Febres‐Roman

Haas

Cowen

1980

Cathet. Cardiovasc. Diagn.

View full text Add to dashboard Cite

show abstract

“…The 7-year mean survival rates were reported as 89 ± 9.3%, 81.9 ± 12.8% and 41.7 ± 22.9%, respectively. An elective change of prosthesis was suggested because of the high risk of embolism and death, in contrast to values reported in other studies [ 9 ].…”

Section: Discussionmentioning

confidence: 83%

Normal function of a 43-year-old Braunwald Cutter heart valve

Jiménez‐Rodrìguez

Críales-Vera

Juárez-Peñaloza

et al. 2018

Oxford Medical Case Reports

View full text Add to dashboard Cite

We present the case of a 72-year-old woman diagnosed with rheumatic fever at the age of 6. In 1972, she was diagnosed with mitral valve insufficiency and mitral valve stenosis, then in 1974, a decision was made to perform mitral valve replacement surgery with a 32-mm Braunwald-Cutter ball cage prosthesis. An echocardiogram performed in 2014 revealed normal biventricular systolic function, mechanical prosthesis in mitral position with maximum speed of 1.9 m/s, maximum gradient of 15 mmHg, mean gradient of 6 mmHg, severe tricuspid valve insufficiency, inferior vena cava measuring 15 mm with more than 50% collapse and pulmonary artery systolic pressure of 40 mmHg. We report the use of the 32-mm Braunwald-Cutter ball cage prosthesis with the longest longevity that remains functional after more than 43 years of implantation.

show abstract